Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases
Authors
Keywords
-
Journal
OncoImmunology
Volume 12, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2023-10-30
DOI
10.1080/2162402x.2023.2261264
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
- (2023) Kristen Mathias et al. ONCOLOGIST
- Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
- (2023) Faisal Fa'ak et al. Journal for ImmunoTherapy of Cancer
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
- (2022) Yared Hailemichael et al. CANCER CELL
- The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
- (2022) Sebastian Bruera et al. Frontiers in Oncology
- Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease
- (2021) Monique K. van der Kooij et al. ANNALS OF INTERNAL MEDICINE
- The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
- (2021) Hui Tang et al. Frontiers in Oncology
- The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases
- (2021) Chunlan Wu et al. Immunotherapy
- Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
- (2021) Lauren J Brown et al. Journal for ImmunoTherapy of Cancer
- Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors
- (2021) Nilasha Ghosh et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.
- (2021) Inderjit Mehmi et al. JOURNAL OF CLINICAL ONCOLOGY
- Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
- (2021) Diana V Maslov et al. Journal for ImmunoTherapy of Cancer
- Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy
- (2021) Florentia Dimitriou et al. EUROPEAN JOURNAL OF CANCER
- Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Fausto Petrelli et al. Cancers
- Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
- (2019) Noha Abdel-Wahab et al. Journal for ImmunoTherapy of Cancer
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
- (2019) Puyuan Xing et al. Journal for ImmunoTherapy of Cancer
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.
- (2018) Kathryn Cecilia Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2018) Sabina Sandigursky et al. Current Rheumatology Reports
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis
- (2018) Min Peng et al. OncoTargets and Therapy
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
- (2017) Corneel Coens et al. LANCET ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autoimmune disease and subsequent digestive tract cancer by histology
- (2011) K. Hemminki et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started